Category: Press releases
EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders i...
Two studies funded by EHA and published in the medical journal Lancet Haematology by a team of researchers from Oxford University and King’s College found that the economic burden of blood disorders (malignant and non-malignant) across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.
Press Release: Economic burden of blood disorders in EU is €23 billion
The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.
SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates am...
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.
Killer antibodies against AML
Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.
Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients
Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the...
The Clot Thickens
Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).
Genome sequencing of thousands of patients with rare blood disorders
Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot.
Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma ...
Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.
Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic...
Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.
The root of evil: pre-leukemic clones that survive chemotherapy are linked to a ...
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission.
Stopping tyrosine kinase inhibitors in a very large cohort of European chronic ...
Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.
Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab
Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will...
A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT...
A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!
EHA Award winners put in the spotlight in Copenhagen
Copenhagen, June 9 2016. At the 21st Congress of the European Hematology Association (EHA) in Copenhagen, in total thirteen hematology researchers will be awarded for their work. Research is the engine that drives improvements in patient care which is why EHA is keen in investing in Awards and Grants to stimulate and support hematology research.
PRESS RELEASE: The future of research in hematology is here
The Hague, January 27, 2016 In the February 2016 issue of Haematologica, critical research of blood and blood-forming organs in Europe is given a boost. The European Hematology Association Roadmap for European Hematology Research: A Consensus Document summarizes the current status of basic, translational and clinical hematology research and identifies areas of unmet scientific and medical need in Europe. It provides guidance for European and national policy makers, funding agencies, charities, research institutes and researchers when they make decisions on initiating or funding research and developing research programs.